AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03450837 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Computed Tomography Angiography
Description: To assess coronary artery plaque and calcification, all participants underwent coronary computed tomography angiography according to the guidelines of the Society of Cardiovascular Computed Tomography (SCCT). All CT scans were acquired in a 320-row detector scanner (AquillionOneTM - Toshiba Medical Systems Corporation, Otawara, Japan) with 0.5-mm thick slices. Acquisition protocol included coronary artery calcium scoring (CACS) and coronary CTA. CACS protocol utilized a 370-ms tube rotation, 120-kV tube voltage, 300-mA tube current, and 320x0.5-mm collimation with 3-mm slice thickness reconstructed images, one heart beat acquisition during diastole.
Study NCT03450837 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Macrophage cholesterol efflux mediated by HDL
Description: Macrophages were incubated with DMEM (Low Glucose, Gibco, Grand Island, New York, USA) containing 1 mg fatty acid free albumin (FAFA) (Sigma-Aldrich, Steinheim, Germany) plus 50 μg acetylated LDL/mL and 0.3 μCi 14C-cholesterol/mL (Amersham Biosciences, UK) for 48h. After washing with PBS/FAFA, cells were incubated in the presence or absence of HDL (50 µg/mL) for 8h. The amount of radioactivity present in the medium at the end of the HDL incubation period will indicate albumin-mediated cholesterol efflux with albumin alone and total efflux with albumin + HDL. Thus, specific HDL-mediated efflux will be calculated, subtracting the albumin-mediated efflux from total efflux
Study NCT04764643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine solution
Description: use N-acetylcysteine solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy
Study NCT04764643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium thiosulfate solution
Description: use sodium thiosulfate solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy
Study NCT02808078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait training with augmented reality
Description: 20 sessions (30 min. duration) over 4 weeks of gait training with augmented reality.
Study NCT02808078 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard training
Description: 20 sessions (30 min. duration) over 4 weeks of gait training without augmented reality.
Study NCT03505034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1\*10\^6 cells/kg, once a month for 4 months
Study NCT02054585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 0.9%
Description: Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid.
Study NCT05170061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 160 mg PO daily for 1 week followed by 320 mg daily for 3 weeks, followed by 1 week down-titration to 160 mg daily
Study NCT05170061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Nebivolol 20 mg daily for 1 week followed by 40 mg daily for 3 weeks, followed by 1 week down-titration to 20 mg daily
Study NCT05170061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol/valsartan
Description: Valsartan/Nebivolol, 160/20 mg daily for 1 week followed by 320/40 mg daily for 3 weeks, followed by 1 week down-titration to 160/20 mg daily
Study NCT00607347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Oral Glucose Tolerance Test
Study NCT04490590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide+ Etoposide
Description: Patients will receive the treatment of and chidamide and etoposide capsule, and those who have achieved CR（complete response）or PR（partial response）or SD(stable disease)will continue the treatment.
Study NCT01745731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.
Description: Proceeds to selective application of stem cells in the portal branches of segments II and III as 10 ml aliquots of taking a time of 4 minutes between each application.
Study NCT02540928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 319 hydrate
Study NCT02540928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03930290 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginal tactile imager
Description: Vaginal elasticity evaluation by vaginal tactile imaging analysis.
Study NCT01290029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Single, oral dose of 0.25 mg/kg cinacalcet
Study NCT02609347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy Group
Description: The manual therapy intervention will be based on the typed of fracture the patient sustained, and their limitations in joint mobility.
Study NCT02609347 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: The sham intervention will consist of soft tissue mobilization and Grade I mobilization at the proximal tib/fib joint.
Study NCT00472810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ologen collagen matrix in glaucoma filtering surgery
Description: If ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
Study NCT00472810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMC in glaucoma filtering surgery
Description: If mitomycin -C is applied, a single cellulose sponge soaked with MMC (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
Study NCT03955796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrophobic IOL
Description: RayOne Hydrophobic Aspheric, hydrophobic IOL
Study NCT03955796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-hydrophobic IOL
Description: RayOne Aspheric, non-hydrophobic IOL
Study NCT03208777 — intervention group
Intervention type: GENETIC
Intervention: taking blood samples
Description: taking blood samples and measure telomeric abnormalities
Study NCT02984202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auditory midbrain implant (AMI)
Study NCT01467726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velusetrag
Description: Capsules
Study NCT01467726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules
Study NCT03573583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: The intensity, volume, tempo, and progression will be based on the Federal Physical Activity guidelines. The resistance training exercises will include mainly multi-joint exercises using selectorized machines. Each session will include upper body exercises (Chest Press, Shoulder Press, Seated Rows, Bicep curls, and Tricep Extensions) and lower body exercises (Leg Press, Leg Extension and Leg Curls, and Calf raise) that will be tailored to the participant needs.
Study NCT03573583 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Successful Aging
Description: The successful aging will attend stretching and health lectures as a group . The topics might include, medication management, disease management (e.g. blood pressure, diabetes, arthritis, dementia, pain management, diet) and other health related matters.
Study NCT02943291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4x4 minutes high intensity interval training
Description: Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
Study NCT02943291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10x1 minute high intensity interval training
Description: Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
Study NCT00808054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA
Description: 0.5g topical EMLA
Study NCT00574873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 500 mg once daily, by mouth (tablet) with food preferably in the morning. Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
Study NCT00574873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib
Description: 400 mg once daily, by mouth (tablet). Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
Study NCT00285428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hA20-humanized anti-CD20 antibody
Description: once weekly iv dosing for 4 weeks
Study NCT00828477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xibrom
Description: Xibrom: two times a day for seven days in the first eye.
Study NCT00828477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevanac
Description: Nevanac: three times a day for seven days in the second eye.
Study NCT04669353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma
Description: approximately 15 cm of whole blood was drawn from the uninvolved arm of each patient in the intervention group (group I) into a 20 ml sterile syringe containing citrate for anticoagulation. The blood was immediately centrifuged at 3200 Revolutions per Minute (PRM). Following 15 minutes of centrifugation, 4 - 5 mL of PRP was obtained. Then, the PRP was buffered by using sodium bicarbonate.
Study NCT01543984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity
Description: Tailored Physical Activity (3\*50 min/week in 10 weeks)
Study NCT01543984 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Counselling
Description: Health guidance (1,5h)
Study NCT00597246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACBC, Methionine
Description: F-18 labeled FACBC is prepared stereo-specifically in a semi-automated, NCA procedure utilizing the General Electric FDG MicroLab, a system employing a quaternary 4-aminopyridinium resin to effect F-18 fluorination. The triflate species is displaced with F-18 fluoride in the MicroLab, and then the 1-t-butyl carbamate-3- trifluoromethane sulfonoxy-1-cyclobutane-1-carboxylic acid methyl ester is hydrolyzed with 1 N HCl. The final product is isotonic and sterile, and has been utilized in animal experiments. The product was obtained in 30% radiochemical yield after 65 minutes from EOB. The radiochemical purity was greater than 95% and no preparative HPLC was required. The procedure could be considered routine, and is performed on the FDG synthetic module without changes either to the programming or to the cassettes.
Study NCT00597246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: GE Advance PET scanner for sequential body imaging
Study NCT01329692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Weeks 1 and 2 consist primarily of a review of current dietary habits with initiation of a food journal; a basic review of macronutrients and metabolism; and the beginning of a weekly exercise regimen. Weeks 3, 4, \& 5 introduces counseling, with specific emphasis on emotional aspects of eating and behavioral modification strategies. Week 6 focuses on the metabolic impact of exercise, and includes an exercise session with a personal trainer. Week 7 incorporates a question and answer session with a sharing of discoveries, as well as an option for additional individual follow-up as needed. During this period, patients will also be given access to an interactive web-based tool providing additional emphasis on the aforementioned components and clinician follow-up.
Study NCT00964587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education + Problem-Solving Training Self-Study
Description: * Education + Problem-Solving Training Self-Study~* One session of Literacy-Adapted Diabetes and CVD Risk Education~* Instructions and a schedule for use of the Literacy-Adapted Problem-Solving Workbook for self-study will be given to each participant.
Study NCT00964587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education + Group Problem-Solving Training
Description: * Education + Group Problem-Solving Training~* One session of the Literacy-Adapted Diabetes and CVD Risk Education~* Group problem-solving training eight, 90-minute sessions
Study NCT00964587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education + Individual Problem-Solving Training
Description: * Education + Individual Problem-Solving Training~* One session of the Literacy-Adapted Diabetes and CVD Risk Education~* Individual problem-solving training (eight, 60-minute sessions)
Study NCT00964587 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: * Packet of print patient education materials about CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA)given at baseline following randomization to Arm 1~* Scripted set of instructions will be given along with a verbal description of the materials and the content provided.
Study NCT04521569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: If the donor lungs are randomized the experimental arm, the administration of Regadenoson will be performed at each study site by a qualified medical professional. The donor lungs will be perfused with Regadenoson at a dosage of 1.44 microgram/kg/min (based on donor's weight) for a minimum of three hours and maximum of four hours, using a pediatric syringe pump into the EVLP circuit (XVIVO Perfusion System). The infusion will begin within 10 minutes of the start of the EVLP procedure. Once the EVLP is complete the lungs are re-flushed with Perfadex solution (removing the Steen™ solution and Regadenoson; standard for EVLP).
Study NCT04521569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: If the donor lungs are randomized to the Steen solution arm, the donor lungs will be perfused with placebo at a rate equivalent to the dosage of Regadenoson (1.44 microgram/kg/min), for a minimum of three hours and maximum of four hours, using the same pediatric syringe pump. The infusion will begin within 10 minutes of the start of the EVLP procedure.
Study NCT02054585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NaCl 0.9 +5% dextrose
Description: Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% + 5% dextrose. The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid.
Study NCT03446781 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EN3835
Description: Collagenase clostridium histolyticum
Study NCT03446781 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04450017 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The demographic, clinical, laboratory, and instrumental data
Description: Measurement of the demographic, clinical data, laboratory data, and instrumental data
Study NCT01593345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobility self-management with Mentor
Description: will be offered an evaluation and treatment plan supervised by a qualified physiotherapist, accompanied by written and visual material to enhance mobility self-management skills, supported by telephone mentoring by physiotherapy students in the Professional Master's program. The components of the mobility self-management program will target skill enhancement of each senior to identify their functional limitations, set realistic goals for mobility improvement, develop a mobility action plan, carry out the plan, and then re-assess their function and mobility. Mobility self-assessment, personalized goals, and the action plan will be incorporated into a personalized workbook that the senior can use to monitor their function profile and serve as a communication aid during health care encounters.
Study NCT01593345 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobility self-management with guidebook
Description: will be mailed an exercise guide targeting the key mobility limitations common in the elderly (range of motion, arm, leg, and core strength, and breathing). This guide has been developed and has been pilot tested on a small number of seniors and has been shown to be acceptable and feasible.
Study NCT02508220 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Syntocinon
Description: Oxytocin nasal spray
Study NCT02508220 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: distilled water in nasal spray
Study NCT04680338 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CMR stress perfusion imaging
Description: CMR stress perfusion imaging with feedback of clinically actionable findings to general practitioner and participant
Study NCT01346475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir
Description: 1000 mg orally three times daily for 5 weeks
Study NCT01346475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: 500 mg orally once daily for 5 weeks
Study NCT04147117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Description: Cervical pessary is a silicone ring with a smaller diameter to be fitted around the cervix and a larger diameter to fix the device to the pelvic floor. It modifies the direction of the cervix to the posterior vaginal wall.
Study NCT00873431 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC47
Description: solution/suspension for i.m. injection dosage: 30/150 mcg frequency: 3 times at Day 0, Day 42 and Day 84
Study NCT00531739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polylactic Acid Sheet
Description: SurgiWrapTM film will be secured in two study areas: directly below the abdominal incision and on the posterior pelvic rim. The film will not be wrapped directly around an anastomosis.
Study NCT01739842 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Kudzu extract
Study NCT01739842 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Kudzu extract
Study NCT03927573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEM3PSCA
Description: Infusion of GEM3PSCA, administered intravenously, continuously over 7 days, 2 cycles
Study NCT03455621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Toothbrushing
Description: Toothbrushing with different amounts of fluoride toothpaste (or a non-fluoride toothpaste as a control)
Study NCT03455621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrushing
Description: Toothbrushing with different amounts of fluoride toothpaste (or a non-fluoride toothpaste as a control)
Study NCT03455621 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Toothbrushing
Description: Toothbrushing with different amounts of fluoride toothpaste (or a non-fluoride toothpaste as a control)
Study NCT00621777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: At each weekly study visit from the baseline visit to study week 11, ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the varenicline condition will receive varenicline at the dose used to attain initial abstinence for 40 weeks.
Study NCT00621777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At each weekly study visit from the baseline visit to study week 11,ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the placebo condition will receive placebo pills for 40 weeks.
Study NCT02533817 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary sugar
Description: This study examined the effect of high intakes of fructose compared to high intakes of glucose in a randomized crossover design. The treatment was in replacement of 20% of the daily caloric requirements for either fructose or glucose for each individual.